These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25014290)

  • 1. [The challenges of nanotechnology for the sanitary vigilance of medication].
    Batista Ade J; Pepe VL
    Cien Saude Colet; 2014 Jul; 19(7):2105-14. PubMed ID: 25014290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacovigilance risk mitigation plans: action in public health to promote the safe use of medication.
    Botelho SF; Reis AM
    Cien Saude Colet; 2015 Dec; 20(12):3897-905. PubMed ID: 26691813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sanitary regulation as part of health policy in Brazil: gaps and challenges].
    Maia C; Guilhem D
    Rev Panam Salud Publica; 2016 May; 39(5):226-231. PubMed ID: 27706402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expert consensus (SBC/SBHCI) on the use of drug-eluting stents: recommendations of the Brazilian society of interventional cardiology/ Brazilian society of cardiology for the Brazilian public single healthcare system.
    Lima VC; Mattos LA; Caramori PR; Perin MA; Mangione JA; Machado BM; Coelho WM; Bueno RR
    Arq Bras Cardiol; 2006 Oct; 87(4):e162-7. PubMed ID: 17128305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Governance and pharmacovigilance in Brazil: a scoping review.
    Moscou K; Kohler JC; MaGahan A
    J Pharm Policy Pract; 2016; 9():3. PubMed ID: 26862438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medication leaflets used by elderly with hypertension: adequacy of information for sanitary regulation and possible implications for health].
    de Lyra Junior DP; Balisa-Rocha BJ; Mesquita AR; da Rocha CE
    Cien Saude Colet; 2010 Sep; 15(6):2917-24. PubMed ID: 20922300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Getting it right the first time: developing nanotechnology while protecting workers, public health, and the environment.
    Balbus JM; Florini K; Denison RA; Walsh SA
    Ann N Y Acad Sci; 2006 Sep; 1076():331-42. PubMed ID: 17119213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.
    Botelho SF; Martins MA; Vieira LB; Reis AM
    J Clin Pharmacol; 2017 Apr; 57(4):493-499. PubMed ID: 27568487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health protection in Brazil: the National Sanitary Surveillance System.
    Seta MH; Oliveira CVDS; Pepe VLE
    Cien Saude Colet; 2017 Oct; 22(10):3225-3234. PubMed ID: 29069179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The precautionary principle: advantages and risks].
    Tubiana M
    J Chir (Paris); 2001 Apr; 138(2):68-80. PubMed ID: 11319454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution and key elements of the Brazilian pharmacovigilance system: a scoping review beginning with the creation of the Brazilian Health Regulatory Agency.
    Mota DM; Vigo Á; Kuchenbecker RS
    Cad Saude Publica; 2018 Oct; 34(10):e00000218. PubMed ID: 30328994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance is... Vigilance.
    Edwards IR; Bencheikh RS
    Drug Saf; 2016 Apr; 39(4):281-5. PubMed ID: 26692393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication advertising in Brazil. Can it be regulated?
    Nascimento AC
    Cien Saude Colet; 2009; 14(3):869-77. PubMed ID: 19547786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacovigilance: a necessary tool].
    Coêlho HL
    Cad Saude Publica; 1998; 14(4):871-5. PubMed ID: 9878921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory Impact Analysis: a new tool for better regulation at ANVISA.
    Alves FN; Peci A
    Rev Saude Publica; 2011 Aug; 45(4):802-5. PubMed ID: 21779641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [On improvement of the mechanism for establishing and changing indicators of quality and food safety in the regulatory and legal acts of the Eurasian Economical Union].
    Arnautov OV
    Vopr Pitan; 2016; 85(1):110-6. PubMed ID: 27228709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.